Fecal immunochemical test
Fecal immunochemical test has been studied in 49 papers since 2014: 3 trials and 21 observational studies in people, 16 reviews; 38 in the past year. The newest paper, Nov 5, 2026: “Diagnostic Accuracy and Colonoscopy-Sparing Potential of RAID-CRC Screen After a Positive Faecal Immunochemical Test”.
49 papers study it19 findingsUpdated
3 new papers in 30 daysSee all 49 papers on fecal immunochemical test
At a glance
The findings reach people, from one lab or study. 8 independent labs in 5 countries; 10 trials, 1 about aging, 3 with no results posted.
“optimal cutoff increased sensitivity (14.3%-35.7%, P < 0.01)”
None of its findings points the other way.
- 8 independent labs in 5 countries
- 10 trials, 1 about aging, 3 with no results posted
- Funders: National Institutes of Health and others
- Human trial3
- Humans21
- In silico9
Studies in people
1 study gave fecal immunochemical test to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
| Randomized trial | Both50-69 yearsMidlife adults; Older adults; healthy adults | United European gastroenterology journal, Feb 20, 2026 |
What did studies of fecal immunochemical test find?
13Studies of fecal immunochemical test measured 13 outcomes; the most studied is mortality (3 studies).
Mortality
downin humans2downin silico1
3 studies
Mortality
downin humans2downin silico1
Fecal immunochemical test decreases mortality in colorectal cancer screening.
“Fecal immunochemical testing (FIT) remains the cornerstone of organized, population-based colorectal cancer (CRC) screening owing to its noninvasive nature, affordability, and proven mortality reduction.”
Reviewin colorectal cancer screening
Clinical endoscopy
Fecal immunochemical test decreases mortality in humans (colorectal cancer).
“The population-based screening programs in all three countries primarily utilize the fecal immunochemical test (FIT) and have demonstrably reduced CRC mortality.”
Reviewcolorectal cancer
Population Colorectal Cancer Screening in Asia: Insights From Established Programs
Journal of gastroenterology and hepatology
Fecal immunochemical test decreases mortality in silico (beginning at age 45 vs standard) (6100 fewer deaths).
“screening at 45 would result in fewer CRC cases (15 070) and CRC deaths (6100) in Canada between 2025 and 2071.”
In silicobeginning at age 45 vs standard
Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?
Journal of the Canadian Association of Gastroenterology
Modeled colonoscopy referrals
downin humans1
1 study
Modeled colonoscopy referrals
downin humans1
Fecal immunochemical test is linked with lower modeled colonoscopy referrals in humans (Exploratory FIT118 threshold compared with FIT100) (149 colonoscopies avoided (11.5%); CRC sensitivity 100.0% (95% CI, 89.7–100.0%)).
“FIT118 alone would avoid 149 colonoscopies (11.5%), with CRC sensitivity of 100.0% (95% CI, 89.7–100.0%)”
HumansExploratory FIT118 threshold compared with FIT100n = 1,291
Diagnostics (Basel, Switzerland)
Sensitivity
upin humans1
1 study
Sensitivity
upin humans1
Fecal immunochemical test increases sensitivity in humans (for colorectal cancer vs advanced neoplasm detection) (78.6% vs. 32.3%).
“FIT showed higher sensitivity for CRC than for AN (78.6% vs. 32.3%)”
Reviewfor colorectal cancer vs advanced neoplasm detection
Cancer research and treatment
Screening costs
downin silico1
1 study
Screening costs
downin silico1
Fecal immunochemical test decreases screening costs in silico (annual screening episode in simulated 2021 cohort) (-94.5% ($22.4 billion savings)).
“Replacing initial colonoscopy screening with FIT reduce total screening costs from US$23.7 billion to US$1.3 billion (94.5% reduction), saving US$22.4 billion.”
In silicoannual screening episode in simulated 2021 cohort
Frontiers in oncology
Cost-effectiveness
upin silico1
1 study
Cost-effectiveness
upin silico1
Fecal immunochemical test improves cost-effectiveness in silico (compared with TCS-based screening).
“FIT-based screening was more cost-effective than TCS-based screening.”
In silicocompared with TCS-based screening
Value in health regional issues
Population health
upin silico1
1 study
Population health
upin silico1
Fecal immunochemical test improves population health in silico (prioritising FITs over colonoscopies in the USA) (5.2 million disability-adjusted life-years per decade).
“Prioritising FITs over colonoscopies in the USA could enhance population health by 5.2 million disability-adjusted life-years per decade.”
In silicoprioritising FITs over colonoscopies in the USAper decade
BMJ public health
Environmental impacts
downin silico1
1 study
Environmental impacts
downin silico1
Fecal immunochemical test decreases environmental impacts in silico (roughly 20 percentage points superior to colonoscopies).
“FITs had the lowest environmental impacts, roughly 20 percentage points superior to colonoscopies”
In silico10 years
BMJ public health
Colorectal cancer
downin silico1−25%
1 study
Colorectal cancer
downin silico1−25%
Fecal immunochemical test decreases colorectal cancer in silico (simulated relative to no screening) (25%).
“Relative to no screening, colonoscopy and FIT reduced late-stage diagnoses by 26% and 25%, respectively, versus 20%-32% for annual MCED screening.”
In silicosimulated relative to no screening
medRxiv : the preprint server for health sciencesPreprint
Colorectal cancer mortality
downin humans1
1 study
Colorectal cancer mortality
downin humans1
Fecal immunochemical test decreases colorectal cancer mortality in humans (asymptomatic, average-risk).
“fecal immunochemical test (FIT) in reducing CRC mortality”
Reviewasymptomatic, average-risk
Cancer research and treatment
Diagnostic specificity for advanced colorectal neoplasia
downin humans1
1 study
Diagnostic specificity for advanced colorectal neoplasia
downin humans1
Fecal immunochemical test decreases diagnostic specificity for advanced colorectal neoplasia in humans (previous nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoff) (95.5%-79.2%, P < 0.01).
“reduced specificity (95.5%-79.2%, P < 0.01)”
Human trialprevious nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoffstooln = 378
Clinical and translational gastroenterology
Detection sensitivity for advanced colorectal neoplasia
upin humans1
1 study
Detection sensitivity for advanced colorectal neoplasia
upin humans1
Fecal immunochemical test increases detection sensitivity for advanced colorectal neoplasia in humans (previous nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoff) (14.3%-35.7%, P < 0.01).
“optimal cutoff increased sensitivity (14.3%-35.7%, P < 0.01)”
Human trialprevious nonadvanced lesions, comparing 26 ng/mL vs standard 100 ng/mL cutoffstooln = 378
Clinical and translational gastroenterology
All 13Fewer
What is fecal immunochemical test linked with?
3Studies link fecal immunochemical test with 3 measures: colorectal cancer, FIT concordance and Colonoscopy demand.
Colorectal cancer
downin humans1downin silico1
2 studies
Colorectal cancer
downin humans1downin silico1
Fecal immunochemical test lowers the risk of colorectal cancer in humans (healthy adults).
“The observed reductions in CRC-related mortality and CRC incidence, which were consistent across both screening strategies, were independent of sex or age.”
Human trialhealthy adults
United European gastroenterology journal
Fecal immunochemical test lowers the risk of colorectal cancer in silico (beginning at age 45 vs standard) (15 070 fewer cases).
“Microsimulation results suggest that screening at 45 would result in fewer CRC cases (15 070) and CRC deaths (6100) in Canada between 2025 and 2071.”
In silicobeginning at age 45 vs standard
Should we screen for colorectal cancer with biennial FIT beginning at age 45 in Canada?
Journal of the Canadian Association of Gastroenterology
FIT concordance
no changein humans1
1 study
FIT concordance
no changein humans1
Fecal immunochemical test is associated with FIT concordance in humans (residual stool samples tested by both at-home and in-laboratory FIT) (93% overall concordance).
“A total of 1079 stool samples were tested using both at-home and in-laboratory FIT methods. Overall concordance was 93%.”
Humansresidual stool samples tested by both at-home and in-laboratory FITstooln = 1,079
Journal of clinical gastroenterology
Colonoscopy demand
upin humans1
1 study
Colonoscopy demand
upin humans1
Fecal immunochemical test predicts colonoscopy demand in humans (CRC screening among FONASA beneficiaries in Chile) (Estimated demand: 440,443 individuals).
“The estimated colonoscopy demand corresponds to 440,443 individuals.”
HumansCRC screening among FONASA beneficiaries in Chilesingle-sample qualitative53.71% womensn = 892
Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
Has fecal immunochemical test been tested in people?
1 of 10 about agingYes: 3 trials and 21 observational studies in people have been published.
About aging
Head to Head Trial of Mailed Cologuard to Mailed FIT
Active, not recruiting
Funding
6 grants since 2016National Cancer Institute$1MNational Institute for Health Research£406KJapan Society for the Promotion of Science¥4.8M
National Institute for Health ResearchSheffield Teaching Hospitals NHS Foundation Trust£256K2025–2027
National Cancer InstituteFred Hutchinson Cancer Center$224K2019–2025
National Institute for Health ResearchAdvanced Expert Systems£150K2020–2021
Gouvernement du Canada | Canadian Institutes of Health ResearchUniversity of CalgaryCA$226K2019–2022
Innovative UKAdvanced Expert Systems£140K2018–2019
Japan Society for the Promotion of ScienceYamaguchi University¥4.8M2016–2019
Contains public sector information licensed under the Open Government Licence v3.0.